Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

(2020) David W. Vredevoogd et al.   CELL

Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder

(2020) Andrea Necchi et al.   EUROPEAN UROLOGY

Tumor Immunology and Tumor Evolution: Intertwined Histories

(2020) Jérôme Galon et al.   IMMUNITY

New predictors for immunotherapy responses sharpen our view of the tumour microenvironment

(2020) Tullia C. Bruno   NATURE

Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis

(2020) Jennifer Kubon et al.   Cancers

Identification of Four Immune Subtypes in Bladder Cancer Based on Immune Gene Sets

(2020) Chaozhi Tang et al.   Frontiers in Oncology

Tumor‑infiltrating M2�macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer

(2019) Yongping Xue et al.   ONCOLOGY REPORTS

DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes

(2019) Thiago Vidotto et al.   Journal for ImmunoTherapy of Cancer

The multifaceted immune regulation of bladder cancer

(2019) Anna K. Schneider et al.   Nature Reviews Urology

Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression

(2019) Sara Matarazzo et al.   Cancers

Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature

(2019) Xuanwen Bao et al.   Frontiers in Oncology

An EMT‐related gene signature for the prognosis of human bladder cancer

(2019) Rui Cao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Bladder Cancer Exhibiting High Immune Infiltration Shows the Lowest Response Rate to Immune Checkpoint Inhibitors

(2019) Shen Pan et al.   Frontiers in Oncology

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma

(2019) Xiangyang Deng et al.   Frontiers in Oncology

Identification of an immunotherapy-responsive molecular subtype of bladder cancer

(2019) Bic-Na Song et al.   EBioMedicine

Atezolizumab for platinum-treated metastatic urothelial carcinoma

(2018) Francesco Massari et al.   LANCET

Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways

(2018) Mathieu Rouanne et al.   WORLD JOURNAL OF UROLOGY

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

(2018) Marcus George Kwesi Cumberbatch et al.   EUROPEAN UROLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer

(2018) Li Wang et al.   Nature Communications

Programmed death ligand‐1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder

(2018) Bo Wang et al.   CANCER SCIENCE

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

(2017) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Clinical and in vitro analysis of Osteopontin as a prognostic indicator and unveil its potential downstream targets in bladder cancer

(2017) Janet P.C. Wong et al.   International Journal of Biological Sciences

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study

(2017) Laimonis Kavalieris et al.   JOURNAL OF UROLOGY

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?

(2016) I. Datar et al.   CLINICAL CANCER RESEARCH

Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma

(2016) Islem Ben Bahria-Sediki et al.   Journal of Translational Medicine

Bladder cancer

(2016) Ashish M Kamat et al.   LANCET

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent

(2015) Noah Simon et al.   Journal of Statistical Software

ImmPort: disseminating data to the public for the future of immunology

(2014) Sanchita Bhattacharya et al.   IMMUNOLOGIC RESEARCH

Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors11Grant support: The Swedish Cancer Society, the Swedish research council, the Nilsson Cancer foundation, the BioCARE Strategic Cancer Research program, the Lund Medical Faculty, and FoU Landstinget Kronoberg and Södra Regionvårdnämnden.

(2014) Gottfrid Sjödahl et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A pan-cancer proteomic perspective on The Cancer Genome Atlas

(2014) Rehan Akbani et al.   Nature Communications

Lack of progress in bladder cancer—what are the obstacles?

(2012) Mark S. Soloway   Nature Reviews Urology

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression

(2010) Minako Hagikura et al.   PATHOLOGY INTERNATIONAL